Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
06185 CANSINOBIO
RTNominal up18.780 +0.420 (+2.288%)
Research Report

29/03/2021 17:23

{I-bank focus}CLSA lifts Cansino Biologics (06185) to HK$310

[ET Net News Agency, 29 March 2021] CLSA lifted its target price for Cansino Biologics
(06185) to HK$310 from HK$53.45 and lowered its rating to "outperform" from "buy" after a
367.5% share price surge since January 2020.
The research house said CanSino Bio's FY2020 net loss widened to Rmb397m driven by R&D
spending on its Ad5-nCoV vaccines (Convidencia), authorised by China and three other
countries with more countries to follow.
CLSA forecast Convidencia to deliver a "bolus injection" to 2021/22/23 revenue of
Rmb17bn/Rmb23.8bn/Rmb21.1bn before declining, leading to profit in 2021. The research
house warned that profit-taking is a possibility given supply chain risk, and it noted
that technical analysis suggests near-term range-bound trading. (KL)

Back to Research Report

Remark: Real time quote last updated: 26/04/2024 13:28
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.